Immune checkpoints, their control by immunotherapy and ovarian cancer

Chinmoy K. Bose

doi:10.5114/wo.2017.70108

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2017
vol. 21

Send email

Copy url:

abstract:

Review paper

Immune checkpoints, their control by immunotherapy and ovarian cancer

Chinmoy K. Bose

Contemp Oncol (Pozn) 2017; 21 (3): 189-196

DOI: https://doi.org/10.5114/wo.2017.70108

Online publish date: 2017/09/29

View full text Get citation

PlumX metrics:

Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovarian cancer. As a new development this subject is experiencing rapid progress and multiple avenues are opening up. However, there are many hurdles to overcome, requiring constant updating, especially for students of ovarian cancer, who are looking at it with much hope.

keywords:

Immune checkpoints, their control by immunotherapy and ovarian cancer

Chinmoy K. Bose

immune checkpoint, T cell, ovarian cancer